^
    3ms
    A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=150, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mezagitamab (TAK-079)
    4ms
    TAK-079-3001: A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (clinicaltrials.gov)
    P3, N=347, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mezagitamab (TAK-079)
    7ms
    A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (clinicaltrials.gov)
    P3, N=347, Not yet recruiting, Takeda
    New P3 trial
    |
    mezagitamab (TAK-079)
    7ms
    A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Takeda
    New P3 trial
    |
    mezagitamab (TAK-079)
    9ms
    TAK-079-3002: A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=171, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mezagitamab (TAK-079)
    10ms
    A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Takeda | Trial completion date: Feb 2025 --> Mar 2026 | Trial primary completion date: Feb 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • pomalidomide • mezagitamab (TAK-079)
    12ms
    A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=171, Not yet recruiting, Takeda
    New P3 trial
    |
    mezagitamab (TAK-079)
    1year
    A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P2, N=41, Completed, Takeda | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    mezagitamab (TAK-079)
    over1year
    A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Takeda | Phase classification: P1b --> P1 | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    lenalidomide • bortezomib • pomalidomide • mezagitamab (TAK-079)
    over1year
    A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=23, Completed, Millennium Pharmaceuticals, Inc. | N=58 --> 23 | Phase classification: P1b --> P1
    Phase classification • Enrollment change • Combination therapy
    |
    mezagitamab (TAK-079)
    almost2years
    A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    mezagitamab (TAK-079)
    almost2years
    A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P1/2, N=27, Terminated, Takeda | Phase classification: P1b/2 --> P1/2 | Active, not recruiting --> Terminated; Enrolment Challenges
    Phase classification • Trial termination • Combination therapy
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • mezagitamab (TAK-079) • subasumstat (TAK-981)